Pluri (NASDAQ:PLUR) Issues Quarterly Earnings Results

Pluri (NASDAQ:PLUR) posted its earnings results on Thursday. The company reported ($0.54) EPS for the quarter, FiscalAI reports. The company had revenue of $0.34 million during the quarter.

Pluri Stock Down 8.8%

Shares of NASDAQ:PLUR traded down $0.12 during midday trading on Thursday, hitting $1.25. 25,375 shares of the stock traded hands, compared to its average volume of 17,332. The business’s 50 day moving average is $1.68 and its two-hundred day moving average is $2.53. The stock has a market capitalization of $13.94 million, a PE ratio of -0.28 and a beta of 0.68. Pluri has a one year low of $1.24 and a one year high of $5.17.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Pluri stock. Jane Street Group LLC acquired a new position in Pluri Inc. (NASDAQ:PLUR) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned 0.14% of Pluri as of its most recent filing with the Securities and Exchange Commission. 16.59% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded shares of Pluri from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 26th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has a consensus rating of “Sell”.

Pluri Company Profile

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.